Denosumab – where does it stand in the GIOP armamentarium?

AbstractWe read with interest, the article on ‘Denosumab vs. risedronate in glucocorticoid‐induced osteoporosis: final results of a 24‐month randomized, double‐blind, double‐dummy trial ‘ by Saag KG et al. [1] Osteoporosis in a setting of glucocorticoid‐induced osteoporosis (GIOP) is challenging because of issues with drug adhere nce (due to the pill burden) and the presence of multiple comorbidities. Denosumab is a welcome addition in the armamentarium of this disease due to its once‐in‐six months dosing, which is associated with better adherence than bisphosphonates[2] and its renal safety [3]. However, certain clarifi cations may further help the readers to understand its applicability and choosing it as an alternative therapy.

Source: Arthritis and Rheumatology - June 18, 2019 Category: Rheumatology Authors: Arghya Chattopadhyay, Shefali K Sharma, Aman Sharma, Sanjay jain, Varun Dhir Tags: Letter to the Editor Source Type: research